Atovaquone Proguanil Fixed-Dose Malaria Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malaria require daily dosing, leading to poor patient compliance and increased risk of malaria due to sub-therapeutic drug concentrations, and struggle with seasonal malaria in endemic areas.
Innovation Solution
Development of a compound according to Formula (I) or its pharmaceutically acceptable salts, which includes specific alkyl, hydroxyalkyl, or haloalkyl groups, and their use in pharmaceutical compositions for the treatment and prophylaxis of malaria, providing a crystalline form characterized by specific X-ray powder diffraction patterns, allowing for improved adherence and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily dosing is required for malaria treatment/prophylaxis, then therapeutic effect is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent applies periodic action by designing a dosing regimen that shifts from frequent daily dosing to less frequent dosing intervals (e.g., every other day or weekly). This is achieved through pharmaceutical compositions containing specific compounds (atovaquone and proguanil hydrochloride) that maintain therapeutic efficacy while allowing extended dosing intervals, thereby improving patient compliance without compromising reliability of therapeutic effect
2Reliability
If daily dosing is required for malaria treatment/prophylaxis, then therapeutic effect is maintained, but treatment complexity increases
Solution Approach 1:
The patent merges two active ingredients (atovaquone and proguanil hydrochloride) into a single fixed-dose combination pharmaceutical composition. This combination approach simplifies the treatment regimen by reducing the number of separate medications patients must manage, while maintaining the synergistic therapeutic effect that requires both compounds. The fixed-dose formulation integrates multiple therapeutic agents into one administrable unit, reducing regimen complexity
3Reliability
If strict dosing schedule is enforced, then therapeutic efficacy is ensured, but patient convenience deteriorates
Solution Approach 1:
The patent implements periodic action by establishing extended dosing intervals (every other day or weekly) rather than strict daily scheduling. The pharmaceutical composition is formulated to maintain adequate drug levels throughout the extended interval, providing therapeutic efficacy while significantly improving patient convenience by reducing dosing frequency and allowing more flexible scheduling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound offers a more convenient dosing regimen and enhanced efficacy in treating and preventing malaria, including multi-drug resistant strains, by maintaining therapeutic drug levels and addressing seasonal challenges.
Implementation Method 1
characterised by an X-ray powder diffraction (XRPD) pattern comprising at least three diffraction angles
Data Source
AI summary
The present application relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, compositions thereof, and their use in the treatment and/or prophylaxis of systemic infections, such as the treatment and/or prophylaxis of systemic parasitic and fungal infections, such as malaria, in particular infection by Plasmodium falciparum.